A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Inclusion Criteria:

• Projected life expectancy of at least 12 weeks.

• Participants must have c-Met overexpressing non-small cell lung cancer (NSCLC) asassessed by an AbbVie designated immunohistochemistry (IHC) laboratory using theVENTANA MET (SP44) RxDx assay.

• Archival or fresh tumor material must be submitted for assessment of c-Met proteinexpression levels during the Pre-Screening period. Tumor material from the primarytumor site and/or metastatic sites are allowed.

• If a participant was prescreened for Study M14-239 but did not enroll, tumormaterial previously submitted for Study M14-239 may be used for Study M18-868Pre-Screening upon confirmation from AbbVie that sufficient evaluable tumormaterial is available (Except China).

• A histologically or cytologically documented non-squamous cell NSCLC that is locallyadvanced or metastatic.

• A known epidermal growth factor receptor (EGFR) activating mutation status.

-- Participants with actionable EGFR activating mutations are not eligible

• Actionable alterations in genes other than EGFR are eligible.

• Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

• An Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1.

• Have received no more than 1 line of prior systemic cytotoxic chemotherapy in thelocally advanced or metastatic setting.

• Neoadjuvant and adjuvant systemic cytotoxic chemotherapy will count as a priorline for eligibility purposes if progression occurred within 6 months of theend of therapy.

• Have progressed on at least 1 line of prior therapy for locally advanced/metastaticNSCLC:

• Participants WITHOUT an actionable gene alteration: must have progressed on (orbe considered ineligible for) platinum-based chemotherapy and immune checkpointinhibitor (as monotherapy or in combination with chemotherapy).

• Participants WITH an actionable gene alteration for which immune checkpointinhibitor therapy is not standard of care (e.g., anaplastic lymphoma kinase [ALK] translocation): must have progressed on (or be considered ineligible for)anti-cancer therapy targeting driver gene alterations and platinum-basedchemotherapy.

• Participants with actionable gene alterations for which immune checkpointinhibitor is standard of care must have also progressed on (or beconsidered ineligible for) immune checkpoint inhibitor (as monotherapy orin combination with chemotherapy).

• Must be considered appropriate for docetaxel therapy based on the assessment of thetreating physician.

• Participants with metastases to the central nervous system (CNS) are eligible onlyafter adequate treatment (such as surgery, radiotherapy, or drug therapy) isprovided and:

• They are asymptomatic and off or on a stable or reducing dose of systemicsteroids (on no more than 10 mg per day [QD] prednisone or equivalent) and/oranticonvulsants for at least 2 weeks prior to randomization.

Exclusion Criteria:

• Evidence of new, untreated CNS metastases or progressing CNS metastases aftertreatment.

• Evidence of leptomeningeal disease.

• Participants with adenosquamous or neuroendocrine histology, nor sarcomatoidfeatures.

• Epidermal growth factor receptor (EGFR) activating mutations.

• Participants who have received prior c-Met-targeted antibodies, prior telisotuzumabvedotin, or prior antibody-drug conjugates either targeting c-Met or consisting ofmonomethylauristatin E..

• Participants who have received prior docetaxel therapy.

• A history of other malignancies except:

• Malignancy treated with curative intent and with no known active diseasepresent for >=2 years before the first dose of study drug and felt to be at lowrisk for recurrence by investigator. Additionally, participants must not bereceiving any ongoing anti-cancer therapy, including maintenance therapy, priorto randomization..

• Adequately treated non-melanoma skin cancer or lentigo maligna without evidenceof disease.

• Adequately treated carcinoma in situ without current evidence of disease.

• A history of idiopathic pulmonary fibrosis, organizing pneumonia (e.g.,bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, orevidence of active pneumonitis on screening chest computed tomography (CT) scan. Ahistory of prior radiation pneumonitis in the radiation field (fibrosis) is notpermitted.

• Unresolved or neuroendocrine histology, nor sarcomatoid features adverse event (AE) >= Grade 2 from prior anticancer therapy, except for alopecia or anemia.Participants with hormone deficiencies caused by prior anticancer therapy who areasymptomatic and on a stable dose of replacement hormone are eligible for study.

• Major surgery within 21 days prior to randomization.

• Clinically significant condition(s) as listed in the protocol.